LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) have received a consensus rating of "Moderate Buy" from the six analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $8.50.

Several equities analysts have issued reports on LFST shares. UBS Group upgraded LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $8.50 price objective for the company in a research report on Tuesday, May 27th. KeyCorp started coverage on LifeStance Health Group in a research report on Tuesday, April 8th. They issued an "overweight" rating and a $9.00 price objective for the company. Canaccord Genuity Group started coverage on LifeStance Health Group in a research report on Thursday, April 3rd. They issued a "buy" rating and a $8.00 price objective for the company. Finally, William Blair reiterated an "outperform" rating on shares of LifeStance Health Group in a research report on Friday, February 28th.

LifeStance Health Group Price Performance

Shares of LFST stock opened at $5.17 on Tuesday. The stock's fifty day simple moving average is $6.11 and its 200 day simple moving average is $7.00. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.32 and a quick ratio of 1.32. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -19.88 and a beta of 1.22. LifeStance Health Group has a one year low of $4.64 and a one year high of $8.61.

Insiders Place Their Bets

In other news, insider Ujjwal Ramtekkar sold 16,000 shares of the company's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $5.94, for a total transaction of $95,040.00. Following the completion of the transaction, the insider now directly owns 113,435 shares of the company's stock, valued at $673,803.90. This represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.20% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Blue Trust Inc. raised its stake in LifeStance Health Group by 124.4% in the fourth quarter. Blue Trust Inc. now owns 3,828 shares of the company's stock valued at $27,000 after buying an additional 2,122 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in LifeStance Health Group in the first quarter valued at approximately $31,000. Xponance Inc. bought a new stake in LifeStance Health Group in the first quarter valued at approximately $69,000. Ameriprise Financial Inc. bought a new stake in LifeStance Health Group in the fourth quarter valued at approximately $87,000. Finally, Kapitalo Investimentos Ltda bought a new stake in LifeStance Health Group in the first quarter valued at approximately $87,000. 85.50% of the stock is owned by institutional investors and hedge funds.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.